Simultaneous optimization of limited sampling points for pharmacokinetic analysis of amrubicin and amrubicinol in cancer patients

Author:

Makino Yoshinori12,Watanabe Michiko12,Makihara Reiko Ando1,Nokihara Hiroshi3,Yamamoto Noboru3,Ohe Yuichiro3,Sugiyama Erika2,Sato Hitoshi2,Hayashi Yoshikazu1

Affiliation:

1. Department of Pharmacy; National Cancer Center Hospital; Tokyo Japan

2. Division of Pharmacokinetics/Pharmacodynamics; Department of Pharmacotherapy; School of Pharmacy; Showa University; Tokyo Japan

3. Department of Thoracic Oncology; National Cancer Center Hospital; Tokyo Japan

Publisher

Wiley

Subject

Oncology,General Medicine

Reference16 articles.

1. The SM-5887 lung cancer study group: A phase II study of SM-5887, a novel 9-aminoanthracycline, for non-small-cell lung cancer;Hiraki;Proceedings of the 18th International Congress of Chemotherapy,1993

2. Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial;Sawa;Investig New Drugs,2006

3. Phase II study of amrubicin in previously untreated patients with extensive disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study;Yana;Investig New Drugs,2007

4. Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC);Kato;2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition),2006

5. In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite;Noguchi;J Cancer Res,1998

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3